A
53.92
-0.11 (-0.20%)
| 前收盘价格 | 54.03 |
| 收盘价格 | 54.10 |
| 成交量 | 4,370,249 |
| 平均成交量 (3个月) | 1,599,824 |
| 市值 | 4,298,372,608 |
| 股市价格/股市净资产 (P/B) | 4.04 |
| 52周波幅 | |
| 利润日期 | 7 Aug 2025 - 11 Aug 2025 |
| 稀释每股收益 (EPS TTM) | -3.75 |
| 总债务/股东权益 (D/E MRQ) | 3.34% |
| 流动比率 (MRQ) | 16.80 |
| 营业现金流 (OCF TTM) | -262.63 M |
| 杠杆自由现金流 (LFCF TTM) | -177.47 M |
| 资产报酬率 (ROA TTM) | -18.52% |
| 股东权益报酬率 (ROE TTM) | -27.92% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看跌 | 看跌 |
| Biotechnology (全球的) | 看跌 | 看跌 | |
| 股票 | Akero Therapeutics, Inc. | 看跌 | 看涨 |
AIStockmoo 评分
1.8
| 分析师共识 | 1.0 |
| 内部交易活动 | NA |
| 价格波动 | -0.5 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 4.0 |
| 平均 | 1.75 |
|
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 1.39% |
| 机构持股比例 | 109.29% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 78.00 (Citigroup, 44.66%) | 购买 |
| 中 | 71.00 (31.68%) | |
| 低 | 64.00 (B of A Securities, 18.69%) | 购买 |
| 平均值 | 71.00 (31.68%) | |
| 总计 | 2 购买 | |
| 平均价格@调整类型 | 43.01 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| B of A Securities | 27 May 2025 | 64.00 (18.69%) | 购买 | 46.00 |
| Citigroup | 13 May 2025 | 78.00 (44.66%) | 购买 | 40.01 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合